| Identification | Back Directory | [Name]
1H-Purine-2,6-dione, 7-[[5-(3,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl]methyl]-3,7-dihydro-1,3-dimethyl-8-(1-piperazinyl)- | [CAS]
2253744-56-6 | [Synonyms]
1H-Purine-2,6-dione, 7-[[5-(3,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl]methyl]-3,7-dihydro-1,3-dimethyl-8-(1-piperazinyl)- | [Molecular Formula]
C20H20Cl2N8O3 | [MOL File]
2253744-56-6.mol | [Molecular Weight]
491.33 |
| Chemical Properties | Back Directory | [Boiling point ]
717.2±70.0 °C(Predicted) | [density ]
1.68±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [form ]
Solid | [pka]
8.51±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
TH5427 is a promising, targeted inhibitor that can be used to further study NUDT5 activity and ADP-ribose metabolism. TH5427, blocks progestin-dependent, PAR-derived nuclear ATP synthesis and subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells. NUDT5 is recently identified as a rheostat of hormone-dependent gene regulation and proliferation in breast cancer cells[1]. | [storage]
4°C, protect from light | [References]
[1]. Page BDG, et al. Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells [published correction appears in Nat Commun. 2019 Nov 1;10(1):5050]. Nat Commun. 2018;9(1):250. |
|
|